Singapore group will develop 'most promising' Ebola vaccine

Hilleman Laboratories, a Singapore-based biotech company, has announced it will advance the rVSV Bundibugyo vaccine toward human clinical trials, Channel NewsAsia reports. The vaccine is designed to protect against Ebola, a serious infectious disease.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton